Genzyme's hylastan misses goal in arthritis trial
Thu Jul 5, 2007 9:14AM EDT
reuters.com
NEW YORK, July 5 (Reuters) - Biotechnology company Genzyme Corp. (GENZ.O: Quote, Profile, Research) said on Thursday that a key arthritis study involving its experimental drug hylastan failed to meet the main goal.
The clinical trial did not meet its primary goal of demonstrating that hylastan provides superior pain relief to steroids, Genzyme said.
((Reporting by Lewis Krauskopf, editing by Gerald E. McCormick; Reuters Messaging: Lewis.Krauskopf.reuters.com@reuters.net; lewis.krauskopf@reuters.com; 646-223-6082)) Keywords: GENZYME/
(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWEN9165
© Reuters 2006. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world. |
